Gonorrhea, the common sexually transmitted disease has evolved to become resistant to all classes of antibiotics save one, say alarmed health professionals.
Accordingly, the U.S. Centers for Disease Control and Prevention (CDC) has said that it will no longer recommend the use of fluoroquinolones due to the emergence of drug-resistant strains in recent years that subdue them.
Yet, hope remains as there is no indication so far that the strains that cause gonorrhea have become or are becoming resistant to the remaining class of antibiotics, known as cephalosporins.
Voicing his concerns, Dr. John Douglas, director of the CDC 's Division of Sexually Transmitted Diseases Prevention, was quoted: "Although the cephalosporins offer several potential options for treating gonorrhea, the lack of additional classes of antibiotics is a serious concern. There are currently no new drugs for gonorrhea in the drug development pipeline."
Experts note that this form of resistant gonorrhea previously common among homosexual and bisexual men, are now seen among heterosexual men.
The CDC has released data indication that gonorrhea has become resistant to fluoroquinolones.
Douglas added:" While we have not seen any significant resistance to cephalosporins to date, any emerging resistance would be a significant public health concern. Clearly, there is an urgent need for new, effective medicines to treat gonorrhea as we are running out of options to treat this serious disease."
The CDC recommends an injectable drug called ceftriaxone, sold by Roche Pharmaceuticals as Rocephin, to treat genital, anal and throat gonorrhea.